Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AVXL Stock Forecast 2025-2026
$3.65
Current Price
$313.08M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to AVXL Price Targets
+1,162.0%
To High Target of $46.00
+1,107.1%
To Median Target of $44.00
+1,052.3%
To Low Target of $42.00
AVXL Price Momentum
-50.1%
1 Week Change
-59.6%
1 Month Change
-51.1%
1 Year Change
-66.1%
Year-to-Date Change
-74.8%
From 52W High of $14.44
+27.4%
From 52W Low of $2.86
📊 TOP ANALYST CALLS
Did AVXL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Anavex is one of their latest high-conviction picks.
Latest AVXL Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, AVXL has a bullish consensus with a median price target of $44.00 (ranging from $42.00 to $46.00). The overall analyst rating is N/A (N/A/10). Currently trading at $3.65, the median forecast implies a 1,107.1% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 1,162.0% upside. Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 1,052.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVXL Analyst Ratings
2
Buy
1
Hold
0
Sell
AVXL Price Target Range
Low
$42.00
Average
$44.00
High
$46.00
Current: $3.65
Latest AVXL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVXL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 29, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Oct 24, 2025 | Jones Trading | Soumit Roy | Hold | Downgrade | $N/A |
| Oct 7, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Oct 2, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Oct 1, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Sep 10, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Sep 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Aug 27, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Aug 22, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Aug 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Aug 4, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Apr 7, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Feb 18, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Feb 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Jan 28, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
| Jan 28, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Jan 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $42.00 |
| Jan 15, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $46.00 |
Anavex Life Sciences Corp. (AVXL) Competitors
The following stocks are similar to Anavex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Anavex Life Sciences Corp. (AVXL) Financial Data
Anavex Life Sciences Corp. has a market capitalization of $313.08M with a P/E ratio of -7.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -43.6%.
Valuation Metrics
Market Cap
$313.08M
Enterprise Value
$387.57M
P/E Ratio
-7.0x
PEG Ratio
-0.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+32.3%
Current Ratio
8.9x
Debt/Equity
0.0x
ROE
-43.6%
ROA
-27.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Anavex Life Sciences Corp. (AVXL) Business Model
About Anavex Life Sciences Corp.
What They Do
Develops therapies for neurodegenerative diseases.
Business Model
Anavex Life Sciences Corp. generates revenue through the research and development of novel biopharmaceutical compounds aimed at treating central nervous system disorders. Its focus on sigma-1 receptor agonists positions the company to explore breakthrough treatments for conditions like Alzheimer's and Parkinson's disease, potentially allowing for partnerships and licensing agreements with larger pharmaceutical companies.
Additional Information
The company plays a significant role in the biotechnology sector, targeting unmet medical needs and contributing to advancements in therapeutic strategies. Anavex's innovative approach not only seeks to improve patient quality of life but also aims to attract investment interest in the pharmaceutical and biotech markets.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
42
CEO
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Country
United States
IPO Year
2015
Website
www.anavex.comAnavex Life Sciences Corp. (AVXL) Latest News & Analysis
Latest News
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
1 day ago
Quick Summary
Anavex Life Sciences plans to request a re-examination after receiving a negative trend vote from CHMP on its marketing application for blarcamesine, an Alzheimer's treatment.
Why It Matters
The negative trend vote from CHMP on Anavex's Alzheimer's drug could hinder regulatory approval, impacting stock prices and investor sentiment surrounding the company's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Blarcamesine treatment showed a significant improvement in ADAS-Cog13 scores, with a difference of -12.78 (P < 0.0001) compared to the ADNI control group at Week 144.
Why It Matters
The significant improvement in ADAS-Cog13 scores with blarcamesine suggests potential efficacy in treating cognitive decline, impacting future market potential and stock values for related biotech companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A presentation highlighted advancements in Alzheimer's care, focusing on the benefits of Oral Blarcamesine for patients and families, indicating potential market interest in Alzheimer's treatments.
Why It Matters
The presentation on Oral Blarcamesine suggests potential advancements in Alzheimer's treatment, which could impact related biotech stocks and market sentiment in healthcare.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Anavex Life Sciences reported positive results from its Phase 2 study of ANAVEX®3-71 for schizophrenia, showing safety and tolerability, supporting further development.
Why It Matters
Positive Phase 2 results for ANAVEX®3-71 in treating schizophrenia enhance Anavex's prospects, potentially increasing stock value and attracting investor interest in neuropsychiatric therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The ANAVEX3-71-002 trial met its primary endpoint, showing safety and tolerability in adult participants, indicating potential for further development.
Why It Matters
Positive trial results for ANAVEX3-71-002 indicate potential for market approval, enhancing the company's growth prospects and attracting investor interest in its future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Anavex Life Sciences reported positive phase 2 results for ANAVEX 3-71 in schizophrenia, showing improved biomarkers and safety. The company has a solid cash position for at least three years.
Why It Matters
Positive phase 2 results for ANAVEX 3-71 enhance Anavex's market potential in schizophrenia treatment, indicating strong growth prospects and financial stability, which could boost investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About AVXL Stock
What is Anavex Life Sciences Corp.'s (AVXL) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Anavex Life Sciences Corp. (AVXL) has a median price target of $44.00. The highest price target is $46.00 and the lowest is $42.00.
Is AVXL stock a good investment in 2026?
According to current analyst ratings, AVXL has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AVXL stock?
Wall Street analysts predict AVXL stock could reach $44.00 in the next 12 months. This represents a 1,107.1% increase from the current price of $3.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Anavex Life Sciences Corp.'s business model?
Anavex Life Sciences Corp. generates revenue through the research and development of novel biopharmaceutical compounds aimed at treating central nervous system disorders. Its focus on sigma-1 receptor agonists positions the company to explore breakthrough treatments for conditions like Alzheimer's and Parkinson's disease, potentially allowing for partnerships and licensing agreements with larger pharmaceutical companies.
What is the highest forecasted price for AVXL Anavex Life Sciences Corp.?
The highest price target for AVXL is $46.00 from Jason Kolbert at D. Boral Capital, which represents a 1,162.0% increase from the current price of $3.65.
What is the lowest forecasted price for AVXL Anavex Life Sciences Corp.?
The lowest price target for AVXL is $42.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 1,052.3% increase from the current price of $3.65.
What is the overall AVXL consensus from analysts for Anavex Life Sciences Corp.?
The overall analyst consensus for AVXL is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $44.00.
How accurate are AVXL stock price projections?
Stock price projections, including those for Anavex Life Sciences Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 16, 2025 2:58 AM UTC